

9 July 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524669

Dear Sir:

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Sale of Equity Investment in Texas Lifesciences Private Limited

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), as amended from time to time, we wish to inform you that the Company has transferred its remaining 543,248 equity shares representing 11% of the paid-up equity share capital of Texas Lifesciences Private Limited ("TLPL") to existing shareholders of TLPL, on 8 July 2026, in accordance with the terms approved by the Board of Directors of the Company. The transaction has been completed for an aggregate consideration of INR 23 million. Consequent upon the aforesaid transfer, the Company's shareholding in TLPL stands reduced from 11% to Nil and the Company no longer holds any equity investment in TLPL.

The above information is being submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take the above information on your record.

Sincerely,
For Hester Biosciences Limited

Vinod Mali
Company Secretary & Compliance Officer